Katherine Poinsatte, PhD,  —

Bone abnormalities were reported in two teenage girls who were on long-term treatment with Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS) associated with a deficiency of the complement factor H (FH). Clinicians are unsure whether these previously undescribed bone abnormalities, including pain, deformities, and joint swelling, were…

Soliris (eculizumab), an approved drug for atypical hemolytic uremic syndrome (aHUS), successfully treated a rare case of the disease in a girl, age 14 months, in China, according to a case study. After eight doses of the therapy, the levels of self-reactive antibodies against complement factor H —…